Go Deep
10x Genomics, Inc.
10x Genomics, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 14,684 | -121.7 | 11.33 | 0.10 | 6,836.83 |
| Oct 2026 | 14,515 | -123.9 | 11.54 | 0.10 | 6,940.66 |
| Oct 2026 | 14,609 | -120.7 | 11.43 | 0.10 | 6,874.23 |
| Oct 2026 | 14,933 | -118.4 | 11.03 | 0.10 | 6,616.79 |
| Oct 2026 | 14,930 | -118.5 | 11.03 | 0.10 | 6,626.72 |
| Oct 2026 | 14,727 | -121.1 | 11.28 | 0.10 | 6,775.58 |
| Oct 2026 | 14,193 | -128.1 | 11.93 | 0.10 | 7,149.47 |
| Oct 2026 | 14,948 | -118.2 | 11.01 | 0.10 | 6,583.76 |
| Oct 2026 | 14,715 | -121.3 | 11.29 | 0.10 | 6,781.66 |
10x Genomics, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 151,036,000.0 | 150,843,000.0 | 166,030,000.0 | 149,002,000.0 |
| Net Profit | -17,931,000.0 | -13,470,000.0 | -16,252,000.0 | -27,472,000.0 |
| EPS | -0.1 | -0.1 | -0.1 | -0.2 |
10x Genomics, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 642,823,000.0 | 610,785,000.0 | 618,727,000.0 | 516,409,000.0 | — |
| Net Profit | -43,544,000.0 | -182,627,000.0 | -255,099,000.0 | -166,000,000.0 | — |
| EPS | -0.3 | -1.5 | -2.2 | -1.5 | — |
10x Genomics, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 1,041,365,000.0 | 918,636,000.0 | 965,143,000.0 | 1,028,980,000.0 | — |
| Total Liabilities | 245,039,000.0 | 208,502,000.0 | 224,100,000.0 | 223,237,000.0 | — |
| Total Equity | 796,326,000.0 | 710,134,000.0 | 741,043,000.0 | 805,743,000.0 | — |
Owes vs Owns
10x Genomics, Inc. owed $0.20 for every $1 it owned in Jun 2026, down from $0.22 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.20× | 0.24× | 0.23× | 0.23× | 0.22× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
10x Genomics, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 50.3%Receivables 7.9%Inventory 5.4%Fixed assets (tangible) 27.6%Intangible assets 6.4%Other assets 2.4%
How it's funded — Dec 2025
Short-term debt 1.1%Long-term debt 7.0%Payables 1.2%Other liabilities 14.2%Shareholders' equity 76.5%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 523.4 | 393.4 | 388.7 | 430.0 |
| Receivables | 82.5 | 88.5 | 114.8 | 104.2 |
| Inventory | 56.3 | 83.1 | 73.7 | 81.6 |
| Fixed assets (tangible) | 287.2 | 309.9 | 344.9 | 359.2 |
| Intangible assets | 66.8 | 20.2 | 21.1 | 27.4 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 25.1 | 23.5 | 21.9 | 26.6 |
| Liabilities & equity | ||||
| Short-term debt | 11.0 | 9.3 | 11.5 | 9.0 |
| Long-term debt | 73.4 | 73.3 | 83.8 | 86.1 |
| Payables | 12.7 | 12.9 | 15.7 | 21.6 |
| Other liabilities | 147.9 | 113.0 | 113.0 | 106.5 |
| Shareholders' equity | 796.3 | 710.1 | 741.0 | 805.7 |
| Net tangible assets | 729.5 | 690.0 | 719.9 | 778.4 |
10x Genomics, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | 136,050,000.0 | 6,664,000.0 | -15,197,000.0 | -33,606,000.0 | — |
| Investing Activities | -13,438,000.0 | -32,631,000.0 | 133,492,000.0 | -350,887,000.0 | — |
| Financing Activities | 6,803,000.0 | 10,914,000.0 | 13,669,000.0 | 15,817,000.0 | — |